Tags: Drug.
Obinutuzumab (called afutuzumab until 2009) is a humanized monoclonal antibody originated by Glycart Biotechnology AG and developed by Biogen Idec Chugai Pharmaceutical Co. and Hoffmann-La Roche Inc. for the treatment of lymphoma. It acts as an immunomodulator.Obinutuzumab targets CD20 and kills B cells.Obinutuzumab was approved under the tradename Gazyva by the US FDA in 2013 for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients.